MILLBRAE, Calif., August 11, 2026
Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients receiving the investigational therapy in the ongoing TeLuRide-006 adaptive Phase 2/3 trial for advanced cutaneous melanoma. The dose selection follows a prespecified analysis of unblinded data reviewed by an independent Data Monitoring Committee (DMC). The DMC recommended that the study continue as planned in all other respects, while 0.60 mg/m² will be used going forward for patients randomized to EIK1001 treatment. The decision is intended to establish an optimized dose as Eikon advances the investigational therapy toward potential registrational development.
EIK1001 Targets Innate and Adaptive Immune Responses
EIK1001 is an investigational, systemically administered dual agonist of Toll-like receptors 7 and 8 (TLR7/8) designed to activate both innate and adaptive immune responses against cancer. According to Eikon, the therapy stimulates myeloid and plasmacytoid dendritic cells, potentially broadening the immune-cell response directed against tumor cells. Earlier Phase 1 studies demonstrated single-agent activity in patients with advanced solid tumors. Eikon believes the mechanism could complement the antitumor immune response generated by PD-(L)1 checkpoint inhibition, providing a rationale for combination development.
TeLuRide-006 Continues as Adaptive Phase 2/3 Study
The TeLuRide-006 trial (NCT06697301) is a global, multicenter, randomized, double-blind, adaptive Phase 2/3 registrational study evaluating EIK1001 or placebo in combination with pembrolizumab as first-line treatment for patients with advanced cutaneous melanoma. Following the prespecified DMC review, the trial will continue in its other planned aspects while future EIK1001-treated participants receive the selected 0.60 mg/m² dose. Dose optimization is an important step in late-stage development, but the current announcement does not provide efficacy results demonstrating improved overall survival.
Advertisement
Eikon Targets Unmet Need in Advanced Melanoma
Advanced cutaneous melanoma remains a challenging cancer in which patients can develop resistance despite advances in immunotherapy and targeted therapies. Eikon is developing EIK1001 as a potential complementary approach to checkpoint inhibitor therapy by activating multiple components of the immune system. The company is focused primarily on oncology and is building a pipeline of investigational medicines using its proprietary technology platform and internally developed and partnered drug candidates. The ongoing TeLuRide-006 study will be important in determining whether EIK1001 can deliver meaningful clinical benefit when combined with pembrolizumab. EIK1001 remains investigational and has not been approved for the treatment of melanoma.
Source:Eikon Therapeutics press release
